Cargando…
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety
BACKGROUND: Multidrug-resistant Gram-negative bacterial (MRGNB) infections represent a major public health threat. Cancer patients and, among them, hematological patients are most vulnerable to these infections. Gut colonization by MRGNB is a common phenomenon occurring during hospitalization and ch...
Autores principales: | Moreno, Ainhoa Fernández, Lavín-Alconero, Lucía, de Ugarriza, Paula López, Blanco, Laura Solán, Hernández, Sara Cáceres, Burgués, Juan Miguel Bergua, de Miguel, María Izquierdo, Huerta, Ana Julia González, Zarzuela, Marta Polo, Boluda, Blanca, Humala, Karem, Calabuig, Maria Luisa, Amigo, Maria Luz, Casas, Marián Cuesta, del Mar García-Saiz, María, Verdugo, Ana Fernández, Domínguez, Javier Fernández, Bernal, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612155/ https://www.ncbi.nlm.nih.gov/pubmed/37891616 http://dx.doi.org/10.1186/s13063-023-07702-5 |
Ejemplares similares
-
Evaluation of a Shotgun Metagenomics Approach for Detection of ESBL- and/or Carbapenemase-Producing Enterobacterales in Culture Negative Patients Recovered from Acute Leukemia
por: Lumbreras-Iglesias, Pilar, et al.
Publicado: (2023) -
Fosfomycin in antimicrobial stewardship programs
por: Rubio, Elena Múñez, et al.
Publicado: (2019) -
In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates
por: Liu, Yanyan, et al.
Publicado: (2019) -
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
por: Rosso-Fernández, Clara, et al.
Publicado: (2015) -
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms
por: Wang, Lei, et al.
Publicado: (2019)